Silence Therapeutics
SLN----
Silence Therapeutics (SLN)
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- --
- Volume
- --
- Turnover
- --
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- --
- Volume Ratio
- --
- Turnover Ratio
- --
Silence Therapeutics Analyst Rating
View MoreForecast & Rating
Jul 22, 2026Price forecast
$29.17164.67%
Forecast & RatingBuy
7analysts
- Strong buy71.43%
- Buy14.29%
- Hold0.00%
- Sell14.29%
- Strong sell0.00%
News
- rttnews · 1 day ago, 03:38 AM
Biotech Stocks At 52-Week Highs - ADVB Surges +73%, BLFS Rises After Acquisition, FBRX, SLN, LBRX
- Market Beat · Jul 17 at 11:40 AM
Silence Therapeutics (NASDAQ:SLN) Sets New 52-Week High - Here's Why
- PUBT · Jul 7 at 08:10 AM
Silence Therapeutics 10% owner Richard Ian Griffiths disposes of ADS-linked common shares worth $16.34 million
- rttnews · Jun 24 at 10:52 PM
Top Biotech Gainers: PLSM Inks Virtual Maternity Care Deal, ICCM Turns Heads, SLN Hits New High
- benzinga_article · Jun 24 at 01:22 PM
This $300 Million Biotech May Be Deeply Mispriced: Analyst
- Quartr · Jun 23 at 03:54 PM
Silence Therapeutics: Divesiran and a robust siRNA pipeline target major unmet needs in PV, dyslipidemia, and obesity
